足月妊娠使用米非司酮促宫颈成熟和引产

• 作 者: Berkane N. Verstraete L. 高雪莲
• 机 构: Serv. de Gynecol.- Obstet ., H.opital Tenon, 4 rue de la Chine, 75020 Paris, France Dr.
• 出 处: 世界核心医学期刊文摘(妇产科学分册)
• 发表日期: 2005年06期
• 关键词: 宫颈成熟 米非司酮 孕妇 耐受性 Bishop 剂量 母儿 安慰剂 用药 产程

This study was undertaken to determine the efficacy of mifepristone for ripening the cervix and inducing labor in term pregnancies. In a double- blind placebo- controlled dose- finding study, 346 women received 50, 100, 200, 400, or 600 mg of mifepristone or placebo. The main endpoint for efficacy was the number of patients in whom labor occurred between 12 and 45 and 54 hours after treatment or who had a Bishop score 6 or greater. Maternal and fetal tolerability was also studied. No significant efficacy was observed whatever the dose of mifepristone. Mifepristone was well tolerated by the mother and fetus. Mifepristone, at doses up to 600 mg, does not induce labor within 54 hours in patients with unfavourable cervical status.

This study was undertaken to determine the efficacy of mifepristone for ripening the cervix and inducing labor in term pregnancies. In a double-blind placebo-controlled dose-finding study, 346 women received 50, 100, 200, 400, or 600 mg of mifepristone or placebo. The main endpoint for efficacy was the number of patients in whom occurred between 12 and 45 and 54 hours after treatment or who had a Bishop score 6 or greater. Maternal and fetal tolerability was also studied. the dose of mifepristone. Mifepristone was well tolerated by the mother and fetus. Mifepristone, at doses up to 600 mg, does not induce labor within 54 hours in patients with unfavorablerable cervical status.